Dr Reddys unveils cancer drug Bortezomib in US

Dr Reddy's launched Bortezomib for Injection 3.5 mg/vial, approved by the United States Food and Drug Administration for the treatment of certain types of cancers in adult patients.

New Delhi: Pharma major Dr Reddy's Laboratories on Wednesday said it has launched Bortezomib for Injection 3.5 mg/vial, indicated for the treatment of certain types of cancers in adult patients, in the US market.

The company has launched Bortezomib for Injection 3.5 mg/vial, approved by the United States Food and Drug Administration (USFDA) via a new drug application pathway for intravenous use only, Dr Reddy's Laboratories said in a statement.

"We're pleased to bring this product to market for the customers and patients who will benefit from this cost-efficient alternative in the market place," Dr Reddy's Laboratories North America Generics CEO Marc Kikuchi said.

Read Also: Chinese strategy: Dr Reddy’s outsources part manufacturing to local parties

This is a great addition to the company's injectable offering in the US market as it continues to augment its portfolio of products in the hospital segment, he added.

The company's product is for intravenous use only and is indicated for the treatment of adult patients with multiple myeloma and for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy, the statement said.

Read Also: FIRST: Dr Reddys forays into nutrition segment with the launch of diabetes drink Celevida in India